The Role of Human Postnatal Bone Marrow-Derived Mesenchymal Stem Cells and Their Importance in Growth, Spinal Cord Injury and Other Neurodegenerative Disorders

Chapter
First Online:

Abstract

Mesenchymal stem cells (MSCs) are pluripotent cells that differentiate into cells of mesodermal origin and transdifferentiate into ectodermal and endodermal cell types. Physiologically, MSCs are primarily responsible for the regeneration and growth of cells and tissues derived from a mesodermal lineage; MSCs form bone, cartilage, muscle, and connective tissue. MSCs can also transdifferentiate with high efficiency to functional neurons: microglia and oligodendrocytes. MSCs respond to environmental cues such as cytokines and these cues affect their development and fate. Since cytokines and other inflammatory mediators are also expected at sites of spinal cord injury (SCI), simple implantation of MSCs and/or their differentiated cells for therapeutic benefits might be premature unless the basic science precedes translational science. This is particularly valid as each individual has a unique immune response. A similar argument could be made for embryonic stem cells (ESCs). However, the unstable behavior of ESC to form tumors, as well as rapid generation of mixed cell types, makes MSCs a more desirable stem cell for translational science. This chapter briefly explains the role of MSCs in normal growth and development before discussing approaches by which MSCs can be applied to SCI repair and other neurodegenerative disorders. The mechanism by which microenvironmental factors can affect stem cell development, growth, and therapies is also discussed. In addition to the potential of direct application of stem cells or their differentiated cells, MSCs can be used as models to understand axonal repair, which could lead to the development of new drugs for SCI. These models could test novel factors to repair neurons. Any identified factor could be delivered directly or by gene therapy. Co-culture methods employing MSCs are significant to long-term investigation for rapid screening of compounds, with simultaneous understanding of repair mechanisms of axotomized neurons. The model could be translated in parallel with other stem cell therapies for SCI repair.

Keywords

Cytokines Mesenchymal stem cells Neurons Spinal cord injury Tissue repair Regeneration Growth Development 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgment

This work was supported by the FM Kirby Foundation.

References

  1. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005;5:629–40.PubMedCrossRefGoogle Scholar
  2. Azari MF, Profyris C, Zang DW, Petratos S, Cheema SS. Induction of endogenous neural precursors in mouse models of spinal cord injury and disease. Eur J Neurol. 2005;12:638–48.PubMedCrossRefGoogle Scholar
  3. Barnabé-Heider F, Frisén J. Stem cells for spinal cord repair. Cell Stem Cell. 2008;3:16–24.PubMedCrossRefGoogle Scholar
  4. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: Nature, biology, and potential applications. Stem Cells. 2001;19:180–92.PubMedCrossRefGoogle Scholar
  5. Bieback K, Kern S, Klüter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells. 2004;22:625–34.PubMedCrossRefGoogle Scholar
  6. Campenot RB. Local control of neurite development of nerve growth factor. Proc Natl Acad Sci. 1977;74:4516–9.PubMedCrossRefGoogle Scholar
  7. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994;84:2068–71.PubMedGoogle Scholar
  8. Chi LY, Yu J, Zhu H, Li XG, Zhu SG, Kindy MS. The dual role of tumor necrosis factor-alpha in the pathophysiology of spinal cord injury. Neurosci Lett. 2008;438:174–9.PubMedCrossRefGoogle Scholar
  9. Chiba S, Lee YM, Zhou W, Freed CR. Noggin enhances dopamine neuron production from human embryonic stem cells and improves behavioral outcome after transplantation into Parkinsonian rats. Stem Cells. 2008;26:2810–20.PubMedCrossRefGoogle Scholar
  10. Deda H, Inci MC, Kürekçi AE, Kayihan K, Ozgün E, Ustünsoy GE, Kocabay S. Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation: 1-year follow-up. Cytotherapy. 2008;10:565–74.PubMedCrossRefGoogle Scholar
  11. Deng J, Petersen BE, Steindler DA, Jorgensen ML, Laywell ED. Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation. Stem Cells. 2006;24:1054–64.PubMedCrossRefGoogle Scholar
  12. Divani AA, Hussain MS, Magal E, Heary RF, Qureshi AI. The use of stem cells’ hematopoietic stimulating factors therapy following spinal cord injury. Ann Biomed Eng. 2007;35:1647–56.PubMedCrossRefGoogle Scholar
  13. Ducker TB, Hamit HF. Experimental treatments of acute spinal cord injury. J Neurosurg. 1969;30:693–7.PubMedCrossRefGoogle Scholar
  14. Fischbach GD, Fischbach RL. Stem cells: science, policy, and ethics. J Clin Invest. 2004;114:1364–70.PubMedGoogle Scholar
  15. Fujiwara T, Kubo T, Koyama Y, Tomita K, Yano K, Tohyama M, Hosokawa K. mRNA expression changes of slit proteins following peripheral nerve injury in the rat model. J. Chem. Neuroanat. 2008;36:170–6.PubMedCrossRefGoogle Scholar
  16. Gao J, Coggeshall RE, Chung JM, Wang J, Wu P. Functional motoneurons develop from human neural stem cell transplants in adult rats. Neuroreport. 2007;18:565–9.PubMedCrossRefGoogle Scholar
  17. Greco SJ, Rameshwar P. Enhancing effect of IL-1alpha on neurogenesis from adult human mesenchymal stem cells: implication for inflammatory mediators in regenerative medicine. J Immunol. 2007;179:3342–50.PubMedGoogle Scholar
  18. Hardy SA, Maltman DJ, Przyborski SA. Mesenchymal stem cells as mediators of neural differentiation. Curr Stem Cell Res Ther. 2008;3:43–52.PubMedCrossRefGoogle Scholar
  19. Harris DT. Cord blood stem cells: a review of potential neurological applications. Stem Cell Rev. 2008;4:269–74.PubMedCrossRefGoogle Scholar
  20. Huang Y, Dai ZQ, Ling SK, Zhang HY, Wan YM, Li YH. Gravity, a regulation factor in the differentiation of rat bone marrow mesenchymal stem cells. J Biomed Sci. 2009;16:87.PubMedCrossRefGoogle Scholar
  21. Johansson S, Price J, Modo M. Effect of inflammatory cytokines on MHC expression and differentiation of human neural stem/progenitor cells. Stem Cells. 2008;26:2444–54.PubMedCrossRefGoogle Scholar
  22. Kang MK, Kang SK. Interleukin-6 induces proliferation in adult spinal cord-derived neural progenitors via the JAK2/STAT3 pathway with EGF-induced MAPK phosphorylation. Cell. Prolif. 2008;41:377–92.PubMedCrossRefGoogle Scholar
  23. Kazemnejad S, Allameh A, Soleimani M, Gharehbaghian A, Mohammadi Y, Amirizadeh N, Jazayery M. Biochemical and molecular characterization of hepatocyte-like cells derived from human bone marrow mesenchymal stem cells on a novel three-dimensional biocompatible nanofibrous scaffold. J Gastroenterol Hepatol. 2008;24:278–87.PubMedCrossRefGoogle Scholar
  24. Kurek JB, Radford AJ, Crump DE, Bower JJ, Feeney SJ, Austin L, Byrne E. LIF (AM424), a promising growth factor for the treatment of ALS. J Neurol Sci. 1998;160:S106–13.PubMedCrossRefGoogle Scholar
  25. Kwon BK, Tetzlaff W, Grauer JN. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J. 2004;4:451–64.PubMedCrossRefGoogle Scholar
  26. Lo WC, Hsu CH, Wu AT, Yang LY, Chen WH, Chiu WT, Lai WF, Wu CH, Gelovani JG, Deng WP. A novel cell-based therapy for contusion spinal cord injury using GDNF-delivering NIH3T3 cells with dual reporter genes monitored by molecular imaging. J Nucl Med. 2008;49:1512–9.PubMedCrossRefGoogle Scholar
  27. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 2000;19:1745–54.PubMedCrossRefGoogle Scholar
  28. Mazzini L, Mareschi K, Ferrero I, Vassallo E, Oliveri G, Boccaletti R, Testa L, Livigni S, Fagioli F. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol Res. 2006;28:523–6.PubMedCrossRefGoogle Scholar
  29. Miller FD. Riding the waves: neural and nonneural origins for mesenchymal stem cells. Cell Stem Cell. 2007;1:129–30.PubMedCrossRefGoogle Scholar
  30. Moviglia GA, Fernandez Viña R, Brizuela JA, Saslavsky J, Vrsalovic F, Varela G, Bastos F, Farina P, Etchegaray G, Barbieri M, Martinez G, Picasso F, Schmidt Y, Brizuela P, Gaeta CA, Costanzo H, Moviglia Brandolino MT, Merino S, Pes ME, Veloso MJ, Rugilo C, Tamer I, Shuster GS. Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy. 2006;8:202–9.PubMedCrossRefGoogle Scholar
  31. O’Donoghue K, Chan J. Human fetal mesenchymal stem cells. Curr Stem Cell Res Ther. 2006;1:371–86.PubMedGoogle Scholar
  32. Olanow CW, Obeso JA, Stocchi F. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Nat Clin Pract Neurol. 2006;2:382–92.PubMedCrossRefGoogle Scholar
  33. Pan W, Cain C, Yu Y, Kastin AJ. Receptor-mediated transport of LIF across blood–spinal cord barrier is upregulated after spinal cord injury. J Neuroimmunol. 2006;174:119–25.PubMedCrossRefGoogle Scholar
  34. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.PubMedCrossRefGoogle Scholar
  35. Planchamp V, Bermel C, Tönges L, Ostendorf T, Kügler S, Reed JC, Kermer P, Bähr M, Lingor P. BAG1 promotes axonal outgrowth and regeneration in vivo via Raf-1 and reduction of ROCK activity. Brain. 2008;131:2606–19.PubMedCrossRefGoogle Scholar
  36. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: Functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 2003;171:3426–34.PubMedGoogle Scholar
  37. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol. 2008;251:131–6.PubMedCrossRefGoogle Scholar
  38. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors. 1993;8:1–9.PubMedCrossRefGoogle Scholar
  39. Roh JK, Jung KH, Chu K. Adult stem cell transplantation in stroke: its limitations and prospects. Curr Stem Cell Res Ther. 2008;3:185–96.PubMedCrossRefGoogle Scholar
  40. Sadan O, Melamed E, Offen D. Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. Expert Opin Biol Ther. 2009;9:1487–97.Google Scholar
  41. Siepe M, Thomsen AR, Duerkopp N, Krause U, Förster K, Hezel P, Beyersdorf F, Schlensak C, Südkamp NP, Bosse R, Niemeyer P. Human neonatal thymus-derived mesenchymal stromal cells: characterization, differentiation, and immunomodulatory properties. Tissue Eng. 2009;15:1787–96.CrossRefGoogle Scholar
  42. Tebar LA, Géranton SM, Parsons-Perez C, Fisher AS, Bayne R, Smith AJ, Turmaine M, Perez-Luz S, Sheasby A, De Felipe C, Ruff C, Raivich G, Hunt SP. Deletion of the mouse RegIIIbeta (Reg2) gene disrupts ciliary neurotrophic factor signaling and delays myelination of mouse cranial motor neurons. Proc Natl Acad Sci. 2008;12:11400–5.CrossRefGoogle Scholar
  43. Thompson JA, Zembrzycki A, Mansouri A, Ziman M. Pax7 is requisite for maintenance of a subpopulation of superior collicular neurons and shows a diverging expression pattern to Pax3 during superior collicular development. BMC Dev Biol. 2008;30:62–79.CrossRefGoogle Scholar
  44. Tonge D, Chan K, Zhu N, Panjwani A, Arno M, Lynham S, Ward M, Snape A, Pizzey J. Enhancement of axonal regeneration by in vitro conditioning and its inhibition by cyclopentenone prostaglandins. J Cell Sci. 2008;1:2565–77.CrossRefGoogle Scholar
  45. Trzaska KA, Kuzhikandathil EV, Rameshwar P. Specification of a dopaminergic phenotype from adult human mesenchymal stem cells. Stem Cells. 2007;25:2797–808.PubMedCrossRefGoogle Scholar
  46. Yamashita T, Deguchi K, Sehara Y, Lukic-Panin V, Zhang H, Kamiya T, Abe K. Therapeutic strategy for ischemic stroke. Neurochem Res. 2009;34:707–10.Google Scholar
  47. Yoo SW, Kim SS, Lee SY, Lee HS, Kim HS, Lee YD, Suh-Kim H. Mesenchymal stem cells promote proliferation of endogenous neural stem cells and survival of newborn cells in a rat stroke model. Exp Mol Med. 2008;31:387–97.CrossRefGoogle Scholar
  48. Yune TY, Chang MJ, Kim SJ, Lee YB, Shin SW, Rhim H, Kim YC, Shin ML, Oh YJ, Han CT, Markelonis GJ, Oh TH. Increased production of tumor necrosis factor-alpha induces apoptosis after traumatic spinal cord injury in rats. J Neurotrauma. 2003;20:207–19.PubMedCrossRefGoogle Scholar
  49. Zeiter S, Lezuo P, Ito K. Effect of TGF beta1, BMP-2 and hydraulic pressure on chondrogenic differentiation of bovine bone marrow mesenchymal stromal cells. Biorheology. 2009;46:45–55.PubMedGoogle Scholar
  50. Zhang X, Zeng Y, Zhang W, Wang J, Wu J, Li J. Co-transplantation of neural stem cells and NT-3-overexpressing Schwann cells in transected spinal cord. J Neurotrauma. 2007;24:1863–77.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Cecile King
    • 1
  • Shyam A. Patel
    • 1
  • Pranela Rameshwar
    • 1
  1. 1.Department of MedicineUMDNJ-New Jersey Medical SchoolNewarkUSA

Personalised recommendations